Research Delta | Ravicti

Ravicti - (1.1 gm/ml; Liquid, Oral)

Generic Name	Glycerol Phenylbutyrate	Innovator	Horizon Pharma
Dosage	1.1 gm/ml; Liquid, Oral	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	Indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients ≥ 2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone
Complexities	Yes

Executive Summary

*** ** *** ***** ** **** **** ** **** ******* '*** *** *, ****, '*** *** **, **** *** *** ************ *********. ****** *** ****** ** ** ******, ******* ******* *** **** ***** *** ********* ** ****** ** *******. ***** ****** ** *** ** ****. ********* *** ***** *** ** ***** ****** ****** *** *** **** ******* ** ****, ***** *** **** ***** *** ******* ** *****. ***** ***** ***** **** ** **** **** ******* ** *** *** *** ************ *********. *** & ***** ***** *** *********** ****** ** *** **** *** ******* ** ******* ***. '***, '***, '*** (*** ***** ******** ** *** *, ****) *** **** ***** ****** '*** ** ******* ******* ** *** ***** *** ******* ** *******. ******* ********** **** ***** *** ******* ********* ** *** ***** ** ***** ***** *** ****** *** ******* ** **** *, ****. ********** *** ******* **** ***. ********* ** *** ***** ** ***** *** *** ****** *** ******* ** **** *, ****. ********* ** ********** **** ***** *** ****** (******), **** ********* *** ****** ***** ******* ** *** *, ****.

Patent Status

Ravicti	Patent 1	Patent 2	Patent 3	Patent 4	Patent 5	Patent 6	Patent 7	Patent 8	Patent 9	Patent 10	Patent 11	Patent 12	Patent 13	Patent 14	Patent 15	Patent 16
* ****	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	* ***** (* ****)
*****	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	* ***** (* ****)
* (**)	*******	*******	*******	*******	*******	*******	*******	* *******	*******	* *******	*******	*******	*******	*******	*******	*******

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
* ****	* \ *	* , ****	*******	****** **********	** , ***
*****	\	*** , ****	*******	****	** , ***
* (**)	\	*** , ***	*******	****	***** * ** * * **

Chronology Of Events

*** **, **** : *** ******** ******* ***** *** **** ** **** ******* '*** *** *, ****, '*** *** **, ****.
*** **, **** : ******* ***** * **** ******* *** ******** ***** *** *** ******* ******** ** ***** ******** ********.
*** **, **** : *** ***** *** ** ***** ****** ****** ** ****** '*** *** *, ****, '*** *** **, **** ** ****.
*** *, **** : ***** ******** ******* ***** *** **** ** **** ******* '*** *** *, ****, '*** *** **, ****.
*** **, **** : ******* ***** * **** ******* ***** ** ******** ***** ** **.
*** *, **** : **** ***** *** ******* '*** *** *, ****, '*** *** **, **** ** *****.
*** **, **** : **** ******** *** ********* ****** ** **** *** **** ******* **** **** ******* ** ****** '***.
*** **, **** : ***** & *** ******** ** **** *** *********** ****** ** ******* '***, '*** **** ******** ** ***** *, ****.
*** **, **** : **** ***** ****** '*** (*** *, ****) ** *******. *** ********** *** ********* **** **** *** *******.
*** **, **** : **** ***** ** ******* *** *********** ****** *** ****** '*** (***** *, ****).
*** **, **** : ********** ********* **** ***** *** *** *** ******* ** **** ** **** ******** ***** & ****. ********* ** *** ***** ** ***** ***** *** ****** *** ******* ** **** *, ****.
*** *, **** : ********** ********* **** *** *** *** *** ******* ** **** ** **** ******** ***** & ****, ******* ****** ***** **** ******* ***** * *** **** ******* *** *** **** ****** '***(**** **, ****).********* ** *** ***** ** ***** *** *** ****** *** ******* ** **** *, ****
*** *, **** : *** *** ********** **** ****** '***(**** **, ****) ********* **** ***.
*** *, **** : **** ******** ******* ***** *** ****-** ******.
*** **, **** : ******* **** **** **** ************ ** ******* '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, *** '***.
*** **, **** : ******* *** **** ******* ********* **********. ** ****** ** *** * **********.
*** **, **** : **** ******** ******* ***** *** **** ** ******.
*** *, **** : ******* **** **** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, *** '***.

Ravicti - (1.1 gm/ml; Liquid, Oral)

Executive Summary

Patent Status

Launch Timelines and Competition

Chronology Of Events

ParaIV Advanced Search

Please contact contact@researchdelta.com to get more details.

Headquarters

Products & Services

Quick Links